Annovis Bio (ANVS) announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis’ clinical trials.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Apple downgraded, Tesla upgraded: Wall Street’s top analyst calls
- Annovis Bio upgraded to Buy at Maxim following buntanetap update
- Annovis Bio upgraded to Buy from Hold at Maxim
- Annovis Bio says FDA clears company to launch Phase 3 Alzheimer’s studies
- Annovis Bio Files Patents for Neurodegenerative Combination Therapies